CytoReason Launches AI Assistant for Drug Development
Tel Aviv's CytoReason launches LINA AI assistant for drug development at JP Morgan Healthcare Conference, speeding research with accurate, biology-grounded.
Jerusalem, 13 January, 2026 (TPS-IL) — Tel Aviv-based CytoReason unveiled LINA, an AI assistant designed to speed up pharmaceutical research, at the JP Morgan Healthcare Conference. LINA helps scientists analyze medical data and understand how diseases work at the molecular level.
Unlike standard AI chatbots that can produce incorrect information, LINA is built on specialized disease models that keep its answers accurate and grounded in real biology. The platform generates analysis code and explains how genes and cells behave in different patients. CytoReason is testing LINA with major pharmaceutical companies including Takeda.





















